Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06340568 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
A Phase 3 study of Endometrial Cancer, sponsored by BioNTech SE.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06340568 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by BioNTech SE. The registered enrollment target is 480 participants, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT06340568, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by BioNTech SE.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \[or docetaxel, if participants cannot take paclitaxel\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (partial response) or disappears (complete response) after treatment. The safety of BNT323 will also be assessed by following the occurrence of unfavorable/adverse effects that are seen after treatment. Other measures include the pharmacokinetics of BNT323 (or how BNT323 moves through and out of the body), the body's immune response, and the impact on quality of life.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG BNT323/DB-1303
Study Locations (20)
Other
- Hospital Británico de Buenos Aires - Buenos Aires
- Investigaciones CORI S.R.L. - La Rioja
- Hospital Provincial del Centenario - Rosario
- Centro Oncológico de Excelencia - San Juan
- Adelaide Oncology & Haematology - Adelaide
- Cancer Research SA - Adelaide
- Gosford Hospital - Gosford
- Frankston Hospital - Melbourne
- Sunshine Hospital - Saint Albans
- Mater Hospital Brisbane - South Brisbane
- Wollongong Hospital - Wollongong
- UZ Leuven - Leuven
- CHU UCL Namur-Sainte-Elisabeth - Namur
- Hospital de Clínicas de Passo Fundo - Passo Fundo
- Irmandade da Santa Casa de Misericórdia de Porto Alegre - Porto Alegre
- Jewish General Hospital - Montreal
- Health Sciences Centre - St. John's
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Nevada
- The Center of Hope Reno - Reno
Ohio
- Miami Valley Hospital South - Centerville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2029-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06340568
The ClinicalTrials.gov registry entry for NCT06340568 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 521-participant average among 181 other Endometrial Cancer trials with a reported enrollment target. The listed sponsor is BioNTech SE, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06340568 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, District of Columbia, Nevada.
Frequently Asked Questions
What is clinical trial NCT06340568 about?
NCT06340568 is a clinical study titled "A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer". The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxoru...
What is the current status of trial NCT06340568?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-06-10. Estimated completion is 2029-11.
What conditions does trial NCT06340568 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT06340568?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), BNT323/DB-1303 (DRUG).
Who is sponsoring clinical trial NCT06340568?
This trial is sponsored by BioNTech SE, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06340568 being conducted?
This trial has 20 study locations across District of Columbia, Nevada, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
RECRUITING · Phase 3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.